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Primary hepatic neuroendocrine carcinoma:
report of two cases and literature review
Zi-Ming Zhao1,2*† , Jin Wang3,4,5†, Ugochukwu C. Ugwuowo6, Liming Wang4,8* and Jeffrey P. Townsend2,7*
Abstract
Background: Primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare. The diagnosis of PHNEC
remains challenging—partly due to its rarity, and partly due to its lack of unique clinical features. Available
treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant,
transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues.
Case presentation: We report two male PHNEC cases and discuss the diagnosis and treatment options.
Both cases presented with abdominal pain; case two also presented with symptoms of jaundice. The initial
diagnosis for both cases was poorly differentiated grade 3 small-cell neuroendocrine carcinoma, based on
imaging characteristics and the pathology of liver biopsies. Final diagnoses of PHNEC were arrived at by
ruling out non-hepatic origins. Case one presented with a large tumor in the right liver lobe, and the
patient was treated with TACE. Case two presented with tumors in both liver lobes, invasions into the left
branch of hepatic portal vein, and metastasis in the hepatic hilar lymph node. This patient was ineligible
for TACE and was allergic to the somatostatin analogue octreotide. This limited treatment options to
supportive therapies such as albumin supplementation for liver protection. Patient one and two died at 61
and 109 days, respectively, following initial hospital admission.
Conclusions: We diagnosed both cases with poorly differentiated grade 3 small-cell PHNEC through
imaging characteristics, immunohistochemical staining of liver biopsies, and examinations to eliminate
non-hepatic origins. Neither TACE nor liver protection appeared to significantly extend survival time of
the two patients, suggesting these treatments may be inadequate to improve survival of patients with
poorly differentiated grade 3 small-cell PHNEC. The prognosis of poorly differentiated grade 3 small-cell
PHNEC is poor due to limited and ineffective treatment options.
Keywords: Primary hepatic neuroendocrine carcinoma, Immunohistochemical staining, Liver biopsy,
Transcatheter arterial chemoembolization, Somatostatin analogue
Background
Primary hepatic neuroendocrine carcinoma (PHNEC) is
a rare neuroendocrine carcinoma (NEC) that originates
from the liver, whereas the vast majority NECs in the
liver are the result of metastases that arise from the
gastrointestinal tract and lungs [1–6]. Symptoms of
PHNEC are not specific, and patients normally present
with abdominal pain [7]. Thus, diagnosis of PHNEC is
very challenging. Liver cancer is commonly diagnosed
initially, typically relying on imaging methods such as
ultrasound, enhanced computer tomography (CT), and
dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI). A diagnosis of NEC then results from
pathological examination of pre-operative liver tumor
biopsy or the surgically resected tumor, and a final
diagnosis of PHNEC largely depends on ruling out non-
hepatic origins [7–9]. Treatment of PHNEC includes
surgical resection of liver (partial hepatectomy), transcathe-
ter arterial chemoembolization (TACE) therapy, liver
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transplantation, chemotherapy, radiotherapy or radiofre-
quency ablation, and administration of somatostatin (i.e.,
growth hormone-inhibiting hormone) analogues, with the
choice of treatment depending on tumor stage, location of
the tumor in the liver, and whether the carcinoma secretes
hormones [7]. Partial hepatectomy is the most common
used treatment, particularly for localized PHNECs [8, 9],
while TACE is normally performed for advanced PHNEC
cases that are poor candidates for resection [7, 10]. By inter-
rupting the blood supply to the tumor while directly deliver-
ing chemotherapeutics, TACE inhibits tumor growth and
extends survival. Somatostatin analogues, such as octreo-
tide, can inhibit secretion of growth hormone by NECs and
prevent tumor proliferation [11].
Here, we report two PHNEC cases that were diagnosed
and treated at our hospital. Since PHNEC is extremely
rare and lacks specific diagnostic symptoms, diagnosis of
each case proceeded through several important stages of
examination. Imaging methods (DCE-MRI and enhanced
CT) revealed a mass in the liver, supporting an initial diag-
nosis of liver cancer. Subsequent immunohistochemical
(IHC) examination of liver biopsies confirmed the diagno-
sis of poorly differentiated NEC. Finally, the primary hep-
atic origin of the detected NEC in each case was arrived at
when gastroscopy, colonoscopy, and positron emission
tomography-computer tomography (PET-CT) examina-
tions eliminated the possibility of the NEC having metas-
tasized to the liver from elsewhere in the body. We
present discussion of the diagnosis, pathology, treatment,
and prognosis of PHNEC.
Case presentation
Case one
A 61-year-old retired Chinese male was admitted into
our hospital in February 2016, presenting with upper ab-
dominal pain for over 1 month (Fig. 1). Liver lesions
were found via ultrasound in another hospital 2 weeks
after symptoms appeared. The patient had a history of
chronic hepatitis B and 20 years of smoking one pack
per day. On inspection, there were no varicose veins; on
palpation, the abdomen was soft, and non-tender; on
percussion, hepatomegaly was detected 5 cm below the
costal margin, and there was no shifting dullness that
would suggest ascites; and on auscultation, bowel sounds
were present (4–5/min). Serum studies indicated high
alpha-fetoprotein (AFP, 878.60 IU/ml, normal range
0.00–6.70), neuron-specific enolase (NSE, 25.51 μg/L,
normal range 0.00–13.00), cancer antigen 125 (CA–125,
107.83 U/mL, normal range 0.00–35.00), and serum
ferritin (SF, 519.55 μg/L, normal range 0.00–322.00).
Abdominal ultrasound revealed a 12 × 11 cm hypere-
choic mass in the right lobe of the liver. DCE-MRI of the
upper abdomen revealed a large mass (17 × 14 × 14 cm)
in the right lobe of the liver, as indicated by a region of
mixed signal intensity (Figs. 2, 3, 4). DCE-MRI showed an
enhanced intensity in the arterial phase, and a rapid
decrease in the intensity of enhancement in the hepatic
parenchymal phase, which supported a diagnosis of liver
cancer (Fig. 4). To confirm the initial diagnosis of liver
cancer, we performed an ultrasound-guided liver biopsy 1
week after admission. Pathological examination of the
tissue confirmed a carcinoma of neuroendocrine cells
based on IHC staining (Fig. 5 and Additional file 1:
Figure S1). Specifically, the tumor was positive for:
cytokeratin AE1/AE3; the neuroendocrine markers
CD56 (also known as neural cell adhesion molecule)
and synaptophysin (Syn); and weakly positive for the
gastrointestinal adenocarcinoma marker villin and the
hepatocellular carcinoma marker HepPar-1. Further-
more, 70% of the tumor cells were positive for the
proliferative marker Ki-67 (i.e., IHC measured a Ki-67
index of 70%), indicating cells are actively dividing.
Thus, IHC examination of the liver biopsy confirmed
the diagnosis of poorly differentiated NEC (grade 3),
a type of small-cell carcinoma, of uncertain origin.
We further investigated the primary origin of the
NEC by fully examining the patient using gastroscopy,
colonoscopy and PET-CT, which failed to find NEC
in any other organ. Therefore, we diagnosed the
patient with PHNEC.
For treatment, 11 days after presentation, we performed
TACE and delivered chemotherapuetics (total dose
oxaliplatin 100 mg, camptothecin 10 mg, and pirarubicin
20 mg) and side effect-mitigating agents (total dose
tropisetron 5 mg and dexamethasone 10 mg) along with
the procedure. One day before TACE, a six-day course of
supplementary intravenous human albumin 20% (20 g per
l00 ml, 100 ml administered per day) was initiated as
supportive therapy to protect the liver. We chose not to
perform surgical resection due to the large size of the
tumor and the overall poor physical condition of this pa-
tient. After 1 month of TACE, DCE-MRI showed partial
tumor necrosis, no increase in the tumor size, and no new
lesions. Two weeks later, the patient was re-admitted into
our hospital and the diagnosis of decompensated cirrhosis
and hepatic encephalopathy were made. The patient died
six days after re-admission (61 days after first admission;
Fig. 1). The probable cause of death was multiple organ
dysfunction syndrome.
Case two
A 69-year-old retired Chinese male was admitted into
our hospital in September 2015, presenting with upper
abdominal pain for the previous month and dark urine
for the previous 2 days (Fig. 6). The patient had hyper-
tension for more than 10 years and diabetes for more
than 20 years, and he had smoked for more than
30 years. Physical examination of the abdomen showed
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Fig. 2 Transverse DCE-MRI of the abdomen shows lesions (arrows) in the right lobe of liver. A large mass in the right hepatic lobe is indicated by
heterogeneous areas of high signal intensity (arrow) in (a) the T2-weighted image, and heterogeneous areas of low intensity signal (arrow) in (b)
the T1-weighted image
Fig. 1 Case one timeline
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no abnormalities. Serum studies indicated high alanine
aminotransferase (ALT, 151 U/L, normal range 9–50),
serum aspartate aminotransferase (AST, 68 U/L, normal
range 15–40), total bilirubin (TB, 36.57 μmol/L, normal
range 2.00–20.00), cancer antigen 19–9 (CA19–9,
160.46 U/ml, normally range 0.00–37.00).
Abdominal ultrasound revealed a solid liver mass,
hypoechoic areas in the left branch of hepatic portal vein
suggesting portal vein invasion by the liver mass, and
dilation of the intrahepatic bile duct in the lateral seg-
ment of the left hepatic lobe suggesting obstruction of
the bile duct. These findings suggested a diagnosis of
liver cancer with portal vein invasion and obstruction of
the bile duct.
Enhanced-CT revealed multiple lesions in the right
and left hepatic lobes, and invasion of the lymph node in
the portal triad (Fig. 7). Multiple masses were evident in
the right hepatic lobe (Fig. 7a, b), a small and patchy
shadow was evident in the left hepatic lobe (Fig. 7c), and
an oval shadow (22 × 38 mm) was evident in the portal
triad, indicating abnormal soft tissue density (Fig. 7d).
Enhanced-CT also suggested an invasion of the left por-
tal vein and mild dilation of the bile duct in the right
hepatic lobe. In summary, enhanced-CT suggested the
diagnosis of intrahepatic malignant tumors, lymph node
metastasis in the portal triad, and invasion of the left
portal vein.
Fig. 3 Coronal DCE-MRI of the abdomen shows liver lesions alongside normal bile ducts. a Localized lesions were prominent in the liver capsule,
and the right diaphragmatic muscle was raised (arrow). b No dilation of the intrahepatic or extrahepatic bile ducts was observed (arrow)
Fig. 4 Transverse DCE-MRI of the abdomen shows a large lesion in the right lobe of the liver in four different phases. DCE-MRI showed hetero-
geneity of signal enhancement in the arterial phase (a), a more obvious heterogeneous signal enhancement in the venous phase (b), slightly
weakened heterogeneous enhancement in the equilibrium phase (c), and a significantly weakened heterogeneous enhancement in the delayed
phase (d)
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During the hospital stay, the patient presented with yel-
low skin and sclera, as well as fever and rash, suggesting
the possibility of autoimmune liver disease. However,
pathological examination confirmed a diagnosis of NEC
(Fig. 8 and Additional file 2: Figure S2). IHC staining indi-
cated that the cells were positive for AE1/AE3, Syn, chro-
mogranin A (CgA) and CD56; and the IHC measured a
Ki-67 index of 95%. Thus, IHC examination of the liver bi-
opsy excluded the possibility of autoimmune liver disease
and confirmed the diagnosis of poorly differentiated NEC
(grade 3), a type of small-cell carcinoma, of uncertain origin.
To confirm the hepatic primary origin of NEC as opposed to
hepatic metastases, we performed gastroscopy, colonoscopy,
and PET-CT examinations, and failed to find NEC in other
organs. Therefore, we diagnosed the patient with PHNEC.
To investigate the causes for the yellow hue of the skin
and sclera, we examined liver biochemical factors, meas-
urement of which confirmed obstructive jaundice, indi-
cated by an elevated total bilirubin level (336.97 μmol/L,
normal range 2.00–20.00) with an increased level of dir-
ect bilirubin (279.76 μmol/L, normal range 0.00–6.00)
and a normal level of indirect bilirubin. Obstructive
jaundice was also consistent with the dilation of the bile
duct that had been revealed by enhanced-CT.
For treatment, we chose not to perform surgical resec-
tion, considering the poor physical condition of the pa-
tient and the extensive spread of the tumor. We further
excluded TACE treatment, because of the extent of the
tumor lesions in both the right and left hepatic lobes, as
well as the left portal vein. While TACE stops tumor
growth by interrupting the blood supply to the tumor,
normal liver cells can continue to survive relying on the
portal vein. Thus, portal vein invasion contraindicated
use of TACE, which would have a high risk of inducing
liver failure. We treated the patient with the somato-
statin analogue octreotide intravenously for 24 h at the
dose of 125 μg/h, with the goal of inhibiting the growth
of the neuroendocrine tumor and extending the patient’s
survival. However, the patient developed itchy red
rashes, which are characteristic of an allergic reaction to
octreotide. Therefore, we discontinued this treatment
immediately. At this point, treatment was limited to pro-
tecting the liver by a four-day course of supplementary
intravenous human albumin 20% (20 g per l00 ml, 50 ml
administered per day). The patient died 109 days after
first admission (Fig. 6).
Discussion
Primary liver cancers are usually hepatocellular carcinoma
(HCC) and rarely neuroendocrine carcinoma, as NEC
normally metastasizes to the liver rather than originating
from it [12–15]. Differential diagnosis of PHNEC versus
metastatic hepatic NEC is important to guide treatment
options and predict outcomes [16–19]. The two cases re-
ported here were both diagnosed as grade 3 poorly differ-
entiated PHNEC.
PHNEC shows no gender predominance [6, 20] and no
risk factors have been reported. A review of PHNEC cases
estimated a mean age of 49.8 (standard deviation: ±16.0)
at the time of diagnosis and that 58.5% (55/94; confidence
interval, CI, 47.9%–68.6%) of patients were female [7]. In
contrast, another literature review estimated a median age
of 66.5 (range: 37–80) and 58.3% (7/12; CI 27%–84%)
male patients [1]. Both cases we presented here were male
with a mean age of 65 (61 and 69) and had been smokers
for at least 20 years; case one had chronic hepatitis B, and
case two had a long history of hypertension and diabetes.
PHNEC is normally detected at a late stage when the
tumor is large, because patients normally present non-
specific clinical symptoms. A review showed that 44%
(37/84; CI 33.2%–55.3%) of patients presented abdom-
inal discomfort, 13.1% (11/84; CI 6.8%–22.2%) of
patients exhibited no symptoms, and 4.8% (4/84; CI
1.3%–11.8%) had jaundice [7]. No standard markers have
been reported to be unique for PHNEC [14]. Both cases we
reported here presented with abdominal pain, and serum
studies showed abnormal tumor markers of AFP, NSE, CA–
125, and SF for case one and CA19–9 for case two.
We diagnosed both patients as having hepatic NEC
using imaging and pathological examination of biopsies.
Based on imaging alone, it is challenging to distinguish
hepatic NEC from other hepatic carcinomas such as
HCC or distinguish primary hepatic from metastatic
hepatic NEC [21]. However, some hepatic NECs exhibit
distinctive cyst-like changes in the liver on MRI and CT
Fig. 5 Microscopic finding of a carcinoma of neuroendocrine cells in the
liver biopsy from case one. Tumor cells exhibit invasive growth with
non-distinct cell borders, light-staining or basophilic cytoplasm, large and
dark nuclei with an irregular shape, visible pathologic mitosis, and
coagulative necrosis. The biopsy section was stained with hematoxylin-
eosin and imaged at 400×. The image was adjusted in Photoshop to
remove the pink background and increase the contrast, and the original
image before adjustment is provided in Additional file 1: Figure S1
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images that can differentiate hepatic NEC from HCC [1,
2, 15, 22–25]. Retrospective investigation showed that
both of our cases presented cyst-like changes in the liver
that are similar to those described in the literature,
which suggested a diagnosis of neuroendocrine carcin-
oma in the liver. With respect to pathological examin-
ation of the biopsies, IHC markers are effective for
identification of primary hepatic neuroendocrine tumors,
and positive staining for Syn and CgA has been used to
support diagnosis of PHNEC [15, 25–27]. A review re-
ported that 84% (26 out of 31) of PHNEC cases showed
positive staining for CgA [13]. Another review reported
that 95% (90 out of 95) of PHNEC cases showed positive
staining for CgA [6]. For the two cases we reported here,
case one exhibited positive staining for Syn, but negative
staining for CgA; whereas case two exhibited positive
staining for both Syn and CgA.
While the general diagnosis of hepatic NEC normally
relies on unique imaging characteristics, IHC markers,
and biopsy, the primary hepatic origin of the NEC is
normally determined by excluding evidence of origins
from other organs [28] given that most hepatic NECs
originate from other tissues and later metastasize to the
liver [29]. Therefore gastroscopy, colonoscopy, and chest
CT including PET-CT are used to finalize the diagnosis
of the hepatic origin of NEC [30]. We diagnosed both
cases with PHNEC accordingly.
The possibility of co-occurrence of HCC and PHNEC is
extremely rare, and we found only 12 cases in the English
literature [31–34] and one in the Korean literature [35].
Interestingly, all 12 cases in the English literature are male
patients in the age distributions of 40 s (one case), 50 s (2
cases), 60 s (4 cases), and 70 s (5 cases), and the Korean
literature reported a case of a 68-year-old female. Almost
Fig. 6 Case two timeline
Zhao et al. BMC Clinical Pathology  (2018) 18:3 Page 6 of 10
all patients (11 out of 13) had documented liver disease,
chronic hepatitis C (6 cases), chronic hepatitis B (4 cases),
and cirrhosis of unknown cause (one case). Our patients
were both males around 60 years of age, and case one had
hepatitis B and was positive for the HCC marker HepPar-
1, suggesting the possibility of co-occurring HCC and
PHNEC. Due to the lack of autopsy samples, we cannot
absolutely exclude this possibility.
While case two presented with symptoms of yellow
skin and sclera, as well as fever and rash during
hospitalization, suggesting a diagnosis of autoimmune
liver disease, we excluded this possibility after perform-
ing liver biopsy. We concluded that the yellow skin and
sclera were caused by obstructive jaundice, suggested by
an elevated level of total bilirubin with an increased dir-
ect bilirubin and normal indirect bilirubin, which is con-
sistent with the imaging results from enhanced-CT that
revealed dilation of the bile duct. However, the degree of
dilation of the extrahepatic bile duct seemed insufficient
to explain the high level of bilirubin. Thus, we
Fig. 7 Enhanced-CT shows multiple lesions in the right and left hepatic lobes in different phases. The right hepatic lobe showed multiple patchy
shadows (the largest 94 × 151 mm) and a circular enhanced lesion (arrow) in the (a) arterial and (b) venous phases. The left hepatic lobe showed
a patchy shadow within the left lobe of liver (arrow) in (c) the venous phase. The portal triad showed an oval shadow (22 × 38 mm) with soft
tissue density (arrow) in (d) the arterial phase
Fig. 8 Microscopic finding of a carcinoma of neuroendocrine cells in the liver biopsy from case two. Tumor cells are clustered and composed of
small cells with little cytoplasm, a high nucleo-cytoplasmic ratio, and dark nuclei with an irregular shape. The biopsy section was stained with
hematoxylin-eosin and imaged at 400×. The image was adjusted in Photoshop to remove the pink background and increase the contrast, and
the original image before adjustment is provided in Additional file 2: Figure S2
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concluded that intrahepatic obstructive jaundice arose as
a consequence of the neuroendocrine carcinoma having
invaded intrahepatic small bile ducts, leading to severe
small bile duct obstruction and high levels of direct bili-
rubin. Case two indicates that yellow skin and sclera
from obstructive jaundice are clinical manifestations
arising as a consequence of bile duct invasion by neuro-
endocrine carcinoma. Thus, jaundice can be consistent
with diagnosis of neuroendocrine carcinoma having
originated in the liver and metastasized to the bile duct.
However, we could not rule out the possibility of cholan-
giocarcinoma or independent primary origin of biliary
NEC in addition to PHNEC, and it is nearly impossible
to distinguish between biliary NEC and cholangiocarci-
noma without biopsy or autopsy [36]. As for case one,
since we did not see either lesions of the bile duct
through multiple imaging approaches or symptoms sug-
gesting obstruction of the bile duct, we excluded the
possibility of cholangiocarcinoma or biliary NEC.
Furthermore, the PHNEC of case two was found to be
bilobar, with tumors in both lobes of the liver, suggesting the
multifocality of the primary. One review reported that 37.2%
(35 out of 94) of PHNEC cases had multiple tumors in-
volved, and 23.4% (22 out of 94) PHNEC were bilobar [7];
another review reported that 23.7% (28 out of 118 cases) of
PHNEC were ‘multicentric’ with a right lobe bias (48.4%,
60/124), and 18.5% (23/124) were bilobar PHNEC [37].
There are multiple treatment options for PHNEC. For
early stage PHNEC, surgical resection of liver tumor tis-
sue or partial hepatectomy is the most common treat-
ment [7], with a five-year survival of 74–78% [4].
Otherwise, treatment options are limited to liver trans-
plantation, TACE, or administration of somatostatin [11,
38–42]. Neither of our two cases was eligible for surgical
resection of the tumor, and liver transplantation was not
performed due to a lack of matched donor livers or fi-
nancial concerns. Accordingly, case one received TACE
treatment. As TACE was contraindicated for case two,
this patient received somatostatin treatment, but his al-
lergic reaction forced us to resort to a supportive ther-
apy of albumin administration to protect the liver.
While the inhibitory hormone somatostatin is useful for al-
leviating the symptoms of the excessive hormones released
by many NECs and inhibiting tumor growth. Particularly, ad-
ministration of a high dose of the radiolabeled somatostatin
analogue 111indium-octreotide, which is typically used to de-
tect neuroendocrine tumors, may hold promise as a thera-
peutic agent [43, 44]. However, it has been reported that
PHNEC is normally endocrinologically silent (i.e. the tumors
do not present with carcinoid syndrome) due to the rapid
degradation of neoplastic-derived hormones via portal circu-
lation, and only 6.8% (6 out of 88 cases) of PHNEC pre-
sented with classic carcinoid syndrome [37], although
another review reported slightly higher 16.7% (14 out of 84)
carcinoid syndrome-presenting cases [7]. Consistently, nei-
ther of our cases presented classic carcinoid syndrome, and
case two was allergic to somatostatin analogue octreotide.
Thus, somatostatin analogues have not been demonstrated
to be therapeutically effective in the treatment of PHNEC
[45, 46], and the potential for allergic reaction to somato-
statin analogues should be anticipated.
Targeted therapies such as treatment with mTOR in-
hibitor (everolimus) or tyrosine kinase inhibitor (raniti-
dine) have shown promise for the treatment of advanced
pancreatic neuroendocrine tumors [47–49]. Everolimus is
currently approved by the FDA for targeted therapy of
well-differentiated, nonfunctional neuroendocrine tumors
of gastrointestinal origin [50]. However, for PHNEC, there
are no approved targeted therapies available [51].
The prognosis of PHNEC depends on the size of the
tumor, the degree of differentiation (well, moderately or
poorly differentiated), histologic grade, Ki-67 index, and
status of metastasis [37, 52–54]. Currently, the overall
prognosis of PHNEC is better than other types of liver
cancer [41, 55]. Median survival is 16.5 months (range,
0.7 to 41.7 months) based on a review of 12 PHNEC pa-
tients [1]. The five-year survival following surgery for all
three differentiation subtypes of PHNEC is about 75%
[37]. After surgical resection, PHNEC can recur or
metastasize in one to 10 years [1, 56, 57]. For poorly dif-
ferentiated NEC, the five-year survival rate is only 6%
[52]. Both cases we reported exhibited the most aggres-
sive and malignant grade 3 poorly differentiated PHNEC
with a high Ki-67 index, surviving only 61 and 109 days,
respectively, after initial hospital admission.
Conclusions
Due to the rarity and asymptomatic clinical features of
PHNEC, the diagnosis of PHNEC is very challenging.
Imaging approaches such as CT and MRI firstly suggest
an initial diagnosis of liver cancer. IHC staining of liver
biopsies can then lead to an accurate diagnosis of NEC,
and subsequent confirmation of hepatic origin of NEC
can be achieved by using gastroscopy, colonoscopy and
PET-CT examinations to rule out non-hepatic primary
sources of the tumor. Survival benefits from treatment
of TACE and somatostatin analogues may be limited,
and the potential for allergic reaction to somatostatin
analogues should be anticipated. Overall, the prognosis
of poorly differentiated grade 3 small-cell PHNEC is
poor due to limited and ineffective treatment options.
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